Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 6/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684687 | 1.00 | GABRA5 (0.78) | GABRA5KDM4EKMT2AALDH1A1GAA | |
| SCHEMBL2683440 | 0.88 | GABRA5 (1.00) | GABRA5KDM4EKMT2AALDH1A1GAA | |
| SCHEMBL2683436 | 0.88 | GABRA5 (1.00) | GABRA5KDM4EKMT2AALDH1A1GAA | |
| SCHEMBL4410068 | 0.82 | GABRA5 (1.00) | GABRA5KDM4EALDH1A1GAALMNA | |
| SCHEMBL2685284 | 0.79 | GABRA5 (0.77) | GABRA5KDM4EKMT2AALDH1A1GAA | |
| SCHEMBL2685279 | 0.79 | GABRA5 (0.77) | GABRA5KDM4EKMT2AALDH1A1GAA | |
| SCHEMBL16290026 | 0.79 | GABRA5 (0.78) | GABRA5KDM4EKMT2AALDH1A1GAA | |
| SCHEMBL16290095 | 0.74 | GABRA5 (0.76) | GABRA5KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL2682566 | 0.73 | KDM4E (0.49) | GABRA5KDM4EKMT2AALDH1A1GAA | |
| SCHEMBL2684857 | 0.71 | GABRA5 (0.48) | GABRA5KDM4EKMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638035-B1 | Triazole derivatives as ligands for Gaba receptors | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | claimed |
| US-8697696-B2 | Triazole compounds II | ROCHE PALO ALTO LLC (US) | 2014-04-15 | — | — | US | claimed |
| EP-2638035-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | claimed |
| WO-2012062623-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | claimed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | claimed |
| EP-2638035-B1 | Triazole derivatives as ligands for Gaba receptors | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-8697696-B2 | Triazole compounds II | ROCHE PALO ALTO LLC (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2638035-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062623-A1 | TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115868-A1 | NOVEL TRIAZOLE COMPOUNDS II | GABRA5, GABRA1, GABRA3 | GABRA5 1/4885KDM4E 1548/4885KMT2A 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.